EA020853B1 - 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина - Google Patents
3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина Download PDFInfo
- Publication number
- EA020853B1 EA020853B1 EA201071269A EA201071269A EA020853B1 EA 020853 B1 EA020853 B1 EA 020853B1 EA 201071269 A EA201071269 A EA 201071269A EA 201071269 A EA201071269 A EA 201071269A EA 020853 B1 EA020853 B1 EA 020853B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methyl
- optionally substituted
- alkylene
- equiv
- solution
- Prior art date
Links
- 239000002461 renin inhibitor Substances 0.000 title abstract description 10
- 229940086526 renin-inhibitors Drugs 0.000 title abstract description 10
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical group 0.000 claims abstract description 375
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 8
- 201000006370 kidney failure Diseases 0.000 claims abstract description 8
- -1 atoms halogen Chemical class 0.000 claims description 215
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 111
- 238000000034 method Methods 0.000 claims description 104
- 150000002367 halogens Chemical class 0.000 claims description 100
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 88
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 85
- 125000005843 halogen group Chemical group 0.000 claims description 78
- 229910052736 halogen Inorganic materials 0.000 claims description 70
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 229920006395 saturated elastomer Polymers 0.000 claims description 64
- 239000001257 hydrogen Substances 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 16
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
- 206010019280 Heart failures Diseases 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 8
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 208000006029 Cardiomegaly Diseases 0.000 claims description 6
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
- 206010063897 Renal ischaemia Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000006806 disease prevention Effects 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 230000036454 renin-angiotensin system Effects 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 206010020571 Hyperaldosteronism Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 230000004410 intraocular pressure Effects 0.000 claims description 5
- 230000002980 postoperative effect Effects 0.000 claims description 5
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 206010038419 Renal colic Diseases 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 101100241486 Caenorhabditis elegans him-10 gene Proteins 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000003386 piperidinyl group Chemical class 0.000 abstract description 2
- 230000007211 cardiovascular event Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 428
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 301
- 150000001412 amines Chemical class 0.000 description 247
- 239000000706 filtrate Substances 0.000 description 236
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 208
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 207
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 177
- 239000007864 aqueous solution Substances 0.000 description 175
- 239000000284 extract Substances 0.000 description 168
- 239000000725 suspension Substances 0.000 description 147
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 142
- 239000012267 brine Substances 0.000 description 137
- 239000011541 reaction mixture Substances 0.000 description 132
- 238000000746 purification Methods 0.000 description 129
- 239000000203 mixture Substances 0.000 description 127
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 121
- 239000012043 crude product Substances 0.000 description 120
- 238000003818 flash chromatography Methods 0.000 description 112
- 239000003921 oil Substances 0.000 description 101
- 235000019198 oils Nutrition 0.000 description 100
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 85
- 239000010410 layer Substances 0.000 description 85
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 84
- 239000012230 colorless oil Substances 0.000 description 83
- 238000006243 chemical reaction Methods 0.000 description 78
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 75
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 70
- 239000000126 substance Substances 0.000 description 70
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 67
- 239000007787 solid Substances 0.000 description 63
- 238000002360 preparation method Methods 0.000 description 54
- 239000000460 chlorine Substances 0.000 description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 239000007789 gas Substances 0.000 description 44
- 239000011734 sodium Substances 0.000 description 42
- 239000003039 volatile agent Substances 0.000 description 41
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
- 238000001914 filtration Methods 0.000 description 35
- 238000003756 stirring Methods 0.000 description 35
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 34
- 230000002152 alkylating effect Effects 0.000 description 31
- 239000012279 sodium borohydride Substances 0.000 description 31
- 229910000033 sodium borohydride Inorganic materials 0.000 description 31
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 30
- 239000003153 chemical reaction reagent Substances 0.000 description 29
- 239000007858 starting material Substances 0.000 description 29
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 150000002466 imines Chemical class 0.000 description 21
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 19
- 235000017557 sodium bicarbonate Nutrition 0.000 description 19
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 19
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 239000012298 atmosphere Substances 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
- 101150026303 HEX1 gene Proteins 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- FBAOFKFCKHJXRU-VOTSOKGWSA-N 2-[(e)-3-methoxyprop-1-enyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COC\C=C\B1OC(C)(C)C(C)(C)O1 FBAOFKFCKHJXRU-VOTSOKGWSA-N 0.000 description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 12
- 101000579218 Homo sapiens Renin Proteins 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 239000011777 magnesium Substances 0.000 description 12
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical class O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
- 108090000783 Renin Proteins 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 9
- 239000002198 insoluble material Substances 0.000 description 9
- 229910052749 magnesium Inorganic materials 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 8
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 8
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 235000017550 sodium carbonate Nutrition 0.000 description 8
- 239000005541 ACE inhibitor Substances 0.000 description 7
- 102100028255 Renin Human genes 0.000 description 7
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- 239000010502 orange oil Substances 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 7
- 229940102001 zinc bromide Drugs 0.000 description 7
- CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical compound COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 6
- VFTIMBRSAGIHRD-UHFFFAOYSA-N 1-cyclopropyl-4-(1-methyl-2-oxopyridin-4-yl)piperidine-3-carboxamide Chemical compound O=C1N(C)C=CC(C2C(CN(CC2)C2CC2)C(N)=O)=C1 VFTIMBRSAGIHRD-UHFFFAOYSA-N 0.000 description 6
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000002051 biphasic effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 5
- 235000019502 Orange oil Nutrition 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- YVWPVDSAXRSSKW-QWHCGFSZSA-N (3s,4r)-4-(1-methyl-2-oxopyridin-4-yl)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound O=C1N(C)C=CC([C@H]2[C@@H](CN(CC2)C(=O)OC(C)(C)C)C(O)=O)=C1 YVWPVDSAXRSSKW-QWHCGFSZSA-N 0.000 description 4
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 4
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 4
- ZWKIJOPJWWZLDI-UHFFFAOYSA-N 4-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1C=CN2 ZWKIJOPJWWZLDI-UHFFFAOYSA-N 0.000 description 4
- WCCLQCBKBPTODV-UHFFFAOYSA-N 6-bromo-1h-indole-3-carbaldehyde Chemical compound BrC1=CC=C2C(C=O)=CNC2=C1 WCCLQCBKBPTODV-UHFFFAOYSA-N 0.000 description 4
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- BWAYIDWRMAEPAF-SNAWJCMRSA-N methyl 3-bromo-5-[(e)-3-methoxyprop-1-enyl]-4-methylbenzoate Chemical compound COC\C=C\C1=CC(C(=O)OC)=CC(Br)=C1C BWAYIDWRMAEPAF-SNAWJCMRSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- OCQWOBDSOBIWQS-UHFFFAOYSA-N 1-[(5-bromo-2,3-dichlorophenyl)methyl]cyclopropan-1-amine Chemical compound BrC=1C=C(C(=C(C1)CC1(CC1)N)Cl)Cl OCQWOBDSOBIWQS-UHFFFAOYSA-N 0.000 description 3
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 3
- VOAVTORWJQDFET-UHFFFAOYSA-N 1-o-tert-butyl 5-o-ethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1,5-dicarboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC(C(=O)OCC)=C1B1OC(C)(C)C(C)(C)O1 VOAVTORWJQDFET-UHFFFAOYSA-N 0.000 description 3
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- GRJZJFUBQYULKL-UHFFFAOYSA-N 4-bromo-1h-indole Chemical compound BrC1=CC=CC2=C1C=CN2 GRJZJFUBQYULKL-UHFFFAOYSA-N 0.000 description 3
- YFTGMMXMLPTTAY-UHFFFAOYSA-N 4-bromo-2-methoxypyridine Chemical compound COC1=CC(Br)=CC=N1 YFTGMMXMLPTTAY-UHFFFAOYSA-N 0.000 description 3
- RPOHXHVHFHRLME-UHFFFAOYSA-N 5-bromo-2,3-dichlorobenzaldehyde Chemical compound ClC1=CC(Br)=CC(C=O)=C1Cl RPOHXHVHFHRLME-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- RYEUDSCFGSLKRL-UHFFFAOYSA-N methyl 3-(2-hydroxyethyl)naphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC(CCO)=CC2=C1 RYEUDSCFGSLKRL-UHFFFAOYSA-N 0.000 description 3
- HQKNBVCXVCXTQD-UHFFFAOYSA-N methyl 3-bromo-5-(3-methoxypropyl)-4-methylbenzoate Chemical compound COCCCC1=CC(C(=O)OC)=CC(Br)=C1C HQKNBVCXVCXTQD-UHFFFAOYSA-N 0.000 description 3
- BAIYNFZNNISXSV-UHFFFAOYSA-N methyl 3-bromonaphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC(Br)=CC2=C1 BAIYNFZNNISXSV-UHFFFAOYSA-N 0.000 description 3
- 238000000199 molecular distillation Methods 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- SMCWNPAVVQIDBM-UHFFFAOYSA-N piperidine-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCN1C(O)=O SMCWNPAVVQIDBM-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 229960001922 sodium perborate Drugs 0.000 description 3
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 3
- ORMGZDWMQGYFJN-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[(3,4-dibromophenyl)methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC=C(Br)C(Br)=C1 ORMGZDWMQGYFJN-UHFFFAOYSA-N 0.000 description 3
- WYFWPBFPUBZDOS-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[(6-formylquinolin-8-yl)methyl]carbamate Chemical compound C=1C(C=O)=CC2=CC=CN=C2C=1CN(C(=O)OC(C)(C)C)C1CC1 WYFWPBFPUBZDOS-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- LSHKEWNEFDSMTN-UHFFFAOYSA-N (3-bromo-5-iodophenyl)methanol Chemical compound OCC1=CC(Br)=CC(I)=C1 LSHKEWNEFDSMTN-UHFFFAOYSA-N 0.000 description 2
- BYGMKLBKRGDVIR-DZGCQCFKSA-N (3s,4r)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-(1,2,3-trimethyl-6-oxopyridin-4-yl)piperidine-3-carboxylic acid Chemical compound CC1=C(C)N(C)C(=O)C=C1[C@H]1[C@H](C(O)=O)CN(C(=O)OC(C)(C)C)CC1 BYGMKLBKRGDVIR-DZGCQCFKSA-N 0.000 description 2
- SYAIOGHBPFQRMP-UONOGXRCSA-N (3s,4r)-4-(1-ethyl-2-oxopyridin-4-yl)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound O=C1N(CC)C=CC([C@H]2[C@@H](CN(CC2)C(=O)OC(C)(C)C)C(O)=O)=C1 SYAIOGHBPFQRMP-UONOGXRCSA-N 0.000 description 2
- WYKWXDANHBFNLV-UHFFFAOYSA-N (5-bromo-2,3-dichlorophenyl)methanol Chemical compound OCC1=CC(Br)=CC(Cl)=C1Cl WYKWXDANHBFNLV-UHFFFAOYSA-N 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- ZKGFMZJIENXHDL-UHFFFAOYSA-N 1,2-dihydropyridine-2,3-dicarboxylic acid Chemical compound OC(=O)C1NC=CC=C1C(O)=O ZKGFMZJIENXHDL-UHFFFAOYSA-N 0.000 description 2
- VFDPVUGQQFPLRW-UHFFFAOYSA-N 1,3-bis(3-methoxypropyl)-2,4-dioxopyrimidine-5-carbaldehyde Chemical compound COCCCN1C=C(C=O)C(=O)N(CCCOC)C1=O VFDPVUGQQFPLRW-UHFFFAOYSA-N 0.000 description 2
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 2
- WHEOMQTYIHCDTQ-UHFFFAOYSA-N 1-(2-methoxyethyl)indole-3-carbaldehyde Chemical compound C1=CC=C2N(CCOC)C=C(C=O)C2=C1 WHEOMQTYIHCDTQ-UHFFFAOYSA-N 0.000 description 2
- UQFDWIPHFBIHPN-UHFFFAOYSA-N 1-(3-methoxypropyl)indole-3-carbaldehyde Chemical compound C1=CC=C2N(CCCOC)C=C(C=O)C2=C1 UQFDWIPHFBIHPN-UHFFFAOYSA-N 0.000 description 2
- DTTOEBBTECCEIX-GOEBONIOSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-(2,3-dimethyl-6-oxo-1H-pyridin-4-yl)piperidine-1,3-dicarboxylate Chemical compound OC1=CC(=C(C(=N1)C)C)[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC DTTOEBBTECCEIX-GOEBONIOSA-N 0.000 description 2
- DAMSVWWAUVXKGG-LSDHHAIUSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-(2-methoxypyridin-4-yl)piperidine-1,3-dicarboxylate Chemical compound COC1=NC=CC(=C1)[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC DAMSVWWAUVXKGG-LSDHHAIUSA-N 0.000 description 2
- ZJSSZRUAJFMIEF-UHFFFAOYSA-N 1-[[2,3-dichloro-5-(4-hydroxybutyl)phenyl]methyl]-4-(1-methyl-2-oxopyridin-4-yl)piperidine-3-carboxamide Chemical compound ClC1=C(C=C(C=C1Cl)CCCCO)CN1CC(C(CC1)C1=CC(N(C=C1)C)=O)C(=O)N ZJSSZRUAJFMIEF-UHFFFAOYSA-N 0.000 description 2
- NYNOBRIFPNFRMC-UHFFFAOYSA-N 1-benzyl-6-bromoindole-3-carbaldehyde Chemical compound C12=CC(Br)=CC=C2C(C=O)=CN1CC1=CC=CC=C1 NYNOBRIFPNFRMC-UHFFFAOYSA-N 0.000 description 2
- DDRDRYIVOWJZAL-UHFFFAOYSA-N 1-chloro-4-(2-methoxyethoxy)-2-methylbenzene Chemical compound COCCOC1=CC=C(Cl)C(C)=C1 DDRDRYIVOWJZAL-UHFFFAOYSA-N 0.000 description 2
- BFIMRKXGLRRBHQ-UHFFFAOYSA-N 1-o-tert-butyl 5-o-ethyl 4-(2,3-dimethyl-6-phenylmethoxypyridin-4-yl)-3,6-dihydro-2h-pyridine-1,5-dicarboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC(C(=O)OCC)=C1C1=CC(OCC=2C=CC=CC=2)=NC(C)=C1C BFIMRKXGLRRBHQ-UHFFFAOYSA-N 0.000 description 2
- UFIVJAIYQNRQOK-UHFFFAOYSA-N 1-prop-2-enylindole-3-carbaldehyde Chemical compound C1=CC=C2N(CC=C)C=C(C=O)C2=C1 UFIVJAIYQNRQOK-UHFFFAOYSA-N 0.000 description 2
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 description 2
- LSWZWCPDVCFYQW-UHFFFAOYSA-N 2-(bromomethyl)-1-chloro-4-(2-methoxyethoxy)benzene Chemical compound COCCOC1=CC=C(Cl)C(CBr)=C1 LSWZWCPDVCFYQW-UHFFFAOYSA-N 0.000 description 2
- IUGSCMVBSMGQAB-UHFFFAOYSA-N 2-(methoxymethoxy)pyridine Chemical compound COCOC1=CC=CC=N1 IUGSCMVBSMGQAB-UHFFFAOYSA-N 0.000 description 2
- RDXPOBDVWNVNQG-UHFFFAOYSA-N 2-chloro-5-(2-methoxyethoxy)benzaldehyde Chemical compound COCCOC1=CC=C(Cl)C(C=O)=C1 RDXPOBDVWNVNQG-UHFFFAOYSA-N 0.000 description 2
- YPCDNKNBOHKKHN-UHFFFAOYSA-N 2-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(N)=O)C(C2CC2)=C1 YPCDNKNBOHKKHN-UHFFFAOYSA-N 0.000 description 2
- ZNOJKOJARUOXIS-UHFFFAOYSA-N 2-methoxy-3,5-bis(3-methoxypropyl)benzaldehyde Chemical compound COCCCC1=CC(CCCOC)=C(OC)C(C=O)=C1 ZNOJKOJARUOXIS-UHFFFAOYSA-N 0.000 description 2
- CNADXZLWTCIEHY-YDFGWWAZSA-N 2-methoxy-3,5-bis[(e)-3-methoxyprop-1-enyl]benzaldehyde Chemical compound COC\C=C\C1=CC(C=O)=C(OC)C(\C=C\COC)=C1 CNADXZLWTCIEHY-YDFGWWAZSA-N 0.000 description 2
- ZLDMZIXUGCGKMB-UHFFFAOYSA-N 3,5-dibromobenzaldehyde Chemical compound BrC1=CC(Br)=CC(C=O)=C1 ZLDMZIXUGCGKMB-UHFFFAOYSA-N 0.000 description 2
- GESWPOYDBJJZGB-UHFFFAOYSA-N 3-(2-azidoethyl)naphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC(CCN=[N+]=[N-])=CC2=C1 GESWPOYDBJJZGB-UHFFFAOYSA-N 0.000 description 2
- BBLZJEBHMWTUSM-UHFFFAOYSA-N 3-(2-methoxyethyl)naphthalene-1-carbaldehyde Chemical compound C1=CC=CC2=CC(CCOC)=CC(C=O)=C21 BBLZJEBHMWTUSM-UHFFFAOYSA-N 0.000 description 2
- LHBWYBNPXJCLRF-UHFFFAOYSA-N 3-(2-methoxyethylamino)naphthalene-1-carboxylic acid Chemical compound C1=CC=CC2=CC(NCCOC)=CC(C(O)=O)=C21 LHBWYBNPXJCLRF-UHFFFAOYSA-N 0.000 description 2
- PLTWZEPCRRUCBS-UHFFFAOYSA-N 3-(3,4-dichloro-5-formylphenyl)propanenitrile Chemical compound ClC1=CC(CCC#N)=CC(C=O)=C1Cl PLTWZEPCRRUCBS-UHFFFAOYSA-N 0.000 description 2
- XGMAMZUFGLBUBO-UHFFFAOYSA-N 3-(3-methoxypropyl)naphthalene-1-carboxylic acid Chemical compound C1=CC=CC2=CC(CCCOC)=CC(C(O)=O)=C21 XGMAMZUFGLBUBO-UHFFFAOYSA-N 0.000 description 2
- HMRSTMZOZAUWRA-NSCUHMNNSA-N 3-[(e)-3-methoxyprop-1-enyl]-5-(trifluoromethyl)benzaldehyde Chemical compound COC\C=C\C1=CC(C=O)=CC(C(F)(F)F)=C1 HMRSTMZOZAUWRA-NSCUHMNNSA-N 0.000 description 2
- YWEFOWVCYAAEGO-UHFFFAOYSA-N 3-[3,4-dichloro-5-(hydroxymethyl)phenyl]propanenitrile Chemical compound OCC1=CC(CCC#N)=CC(Cl)=C1Cl YWEFOWVCYAAEGO-UHFFFAOYSA-N 0.000 description 2
- GVZKZQHWBFQYBO-UHFFFAOYSA-N 3-benzyl-5-methylbenzaldehyde Chemical compound O=CC1=CC(C)=CC(CC=2C=CC=CC=2)=C1 GVZKZQHWBFQYBO-UHFFFAOYSA-N 0.000 description 2
- GMOYAVWZCRFEMU-UHFFFAOYSA-N 3-bromo-5-(3-ethoxypropyl)-4-methylbenzaldehyde Chemical compound CCOCCCC1=CC(C=O)=CC(Br)=C1C GMOYAVWZCRFEMU-UHFFFAOYSA-N 0.000 description 2
- JJRFLJGIKLOFLJ-UHFFFAOYSA-N 3-bromo-5-(3-methoxyprop-1-ynyl)-4-methylbenzoic acid Chemical compound COCC#CC1=CC(C(O)=O)=CC(Br)=C1C JJRFLJGIKLOFLJ-UHFFFAOYSA-N 0.000 description 2
- YUICBFQYIAUOOY-UHFFFAOYSA-N 3-bromo-5-(3-methoxypropyl)benzaldehyde Chemical compound COCCCC1=CC(Br)=CC(C=O)=C1 YUICBFQYIAUOOY-UHFFFAOYSA-N 0.000 description 2
- PCRLZGCXLNNMFL-UHFFFAOYSA-N 3-bromo-5-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC(Br)=CC(C=O)=C1 PCRLZGCXLNNMFL-UHFFFAOYSA-N 0.000 description 2
- SDBFXAWTUIGKOB-UHFFFAOYSA-N 3-bromo-5-[(3-fluorophenyl)methyl]-4-methylbenzaldehyde Chemical compound CC1=C(Br)C=C(C=O)C=C1CC1=CC=CC(F)=C1 SDBFXAWTUIGKOB-UHFFFAOYSA-N 0.000 description 2
- GFUQFXFLXPKSJX-ONEGZZNKSA-N 3-bromo-5-[(e)-3-methoxyprop-1-enyl]-4-methylbenzaldehyde Chemical compound COC\C=C\C1=CC(C=O)=CC(Br)=C1C GFUQFXFLXPKSJX-ONEGZZNKSA-N 0.000 description 2
- FXPSGMULWRTWJU-UHFFFAOYSA-N 3-bromo-5-[3-(difluoromethoxy)propyl]-4-methylbenzaldehyde Chemical compound CC1=C(Br)C=C(C=O)C=C1CCCOC(F)F FXPSGMULWRTWJU-UHFFFAOYSA-N 0.000 description 2
- XVFGERBEZKEGSS-UHFFFAOYSA-N 3-bromo-5-hydroxybenzaldehyde Chemical compound OC1=CC(Br)=CC(C=O)=C1 XVFGERBEZKEGSS-UHFFFAOYSA-N 0.000 description 2
- XZXJUWDREBPKRI-UHFFFAOYSA-N 3-bromo-5-iodobenzaldehyde Chemical compound BrC1=CC(I)=CC(C=O)=C1 XZXJUWDREBPKRI-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- FASUFOTUSHAIHG-UHFFFAOYSA-N 3-methoxyprop-1-ene Chemical compound COCC=C FASUFOTUSHAIHG-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- SVLZRCRXNHITBY-UHFFFAOYSA-N 4-chloro-1h-indole Chemical compound ClC1=CC=CC2=C1C=CN2 SVLZRCRXNHITBY-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- ZCJFHNXOZJBZIA-UHFFFAOYSA-N 5-(3-methoxypropyl)-2-methylsulfanylbenzaldehyde Chemical compound COCCCC1=CC=C(SC)C(C=O)=C1 ZCJFHNXOZJBZIA-UHFFFAOYSA-N 0.000 description 2
- ZCZLDHYJFFDDOE-UHFFFAOYSA-N 5-bromo-2,3-dimethylbenzoic acid Chemical compound CC1=CC(Br)=CC(C(O)=O)=C1C ZCZLDHYJFFDDOE-UHFFFAOYSA-N 0.000 description 2
- VPGFOZUFWWPXBG-NSCUHMNNSA-N 6-[(e)-3-methoxyprop-1-enyl]-2,3-dihydroinden-1-one Chemical compound COC\C=C\C1=CC=C2CCC(=O)C2=C1 VPGFOZUFWWPXBG-NSCUHMNNSA-N 0.000 description 2
- FSGZYMWLXQNBGI-UHFFFAOYSA-N 6-[[tert-butyl(dimethyl)silyl]oxymethyl]quinoline-8-carbaldehyde Chemical compound N1=CC=CC2=CC(CO[Si](C)(C)C(C)(C)C)=CC(C=O)=C21 FSGZYMWLXQNBGI-UHFFFAOYSA-N 0.000 description 2
- PEENKJZANBYXNB-UHFFFAOYSA-N 6-bromo-1H-indole-3-carbaldehyde Natural products BrC1=CC=C2NC=C(C=O)C2=C1 PEENKJZANBYXNB-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- ALKXELCMIXGBSG-UHFFFAOYSA-N CN1C(C=C(C=C1)N1CC(CCC1)C(=O)N)=O Chemical compound CN1C(C=C(C=C1)N1CC(CCC1)C(=O)N)=O ALKXELCMIXGBSG-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000003858 Chymases Human genes 0.000 description 2
- 108090000227 Chymases Proteins 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 101000587820 Homo sapiens Selenide, water dikinase 1 Proteins 0.000 description 2
- 101000701815 Homo sapiens Spermidine synthase Proteins 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 102100030413 Spermidine synthase Human genes 0.000 description 2
- 238000007295 Wittig olefination reaction Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- KIANHEXMRROHSR-UHFFFAOYSA-N [3,4-dichloro-5-[[cyclopropyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]methyl methanesulfonate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(COS(C)(=O)=O)=CC(Cl)=C1Cl KIANHEXMRROHSR-UHFFFAOYSA-N 0.000 description 2
- XQTWQRROFKBPEH-UHFFFAOYSA-N [3-(2-methoxyethyl)naphthalen-1-yl]methanol Chemical compound C1=CC=CC2=CC(CCOC)=CC(CO)=C21 XQTWQRROFKBPEH-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- JZAVUEYXSQMKLU-UHFFFAOYSA-N ethyl 3-bromo-5-(3-ethoxypropyl)-4-methylbenzoate Chemical compound CCOCCCC1=CC(C(=O)OCC)=CC(Br)=C1C JZAVUEYXSQMKLU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 2
- DTKMKZYEOXZPQZ-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=C[C-]=C1 DTKMKZYEOXZPQZ-UHFFFAOYSA-M 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- OWLXUKSNAXEMNS-UHFFFAOYSA-N methyl 3-(2-acetamidoethyl)naphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC(CCNC(C)=O)=CC2=C1 OWLXUKSNAXEMNS-UHFFFAOYSA-N 0.000 description 2
- KSWBHMXSXXNLLZ-UHFFFAOYSA-N methyl 3-(2-aminoethyl)naphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC(CCN)=CC2=C1 KSWBHMXSXXNLLZ-UHFFFAOYSA-N 0.000 description 2
- KRIDRNUFAGHLIL-UHFFFAOYSA-N methyl 3-(2-methoxyethyl)naphthalene-1-carboxylate Chemical compound C1=CC=CC2=CC(CCOC)=CC(C(=O)OC)=C21 KRIDRNUFAGHLIL-UHFFFAOYSA-N 0.000 description 2
- QHOCDFOBPDBARM-UHFFFAOYSA-N methyl 3-(2-methoxyethylamino)naphthalene-1-carboxylate Chemical compound C1=CC=CC2=CC(NCCOC)=CC(C(=O)OC)=C21 QHOCDFOBPDBARM-UHFFFAOYSA-N 0.000 description 2
- MRLMUXRDGTZDIZ-UHFFFAOYSA-N methyl 3-(2-methylsulfonyloxyethyl)naphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC(CCOS(C)(=O)=O)=CC2=C1 MRLMUXRDGTZDIZ-UHFFFAOYSA-N 0.000 description 2
- LZDFVJJZPOMABZ-UHFFFAOYSA-N methyl 3-(3-methoxypropyl)naphthalene-1-carboxylate Chemical compound C1=CC=CC2=CC(CCCOC)=CC(C(=O)OC)=C21 LZDFVJJZPOMABZ-UHFFFAOYSA-N 0.000 description 2
- WFJZQSOLPXUBDT-AATRIKPKSA-N methyl 3-[(e)-3-methoxyprop-1-enyl]naphthalene-1-carboxylate Chemical compound C1=CC=CC2=CC(/C=C/COC)=CC(C(=O)OC)=C21 WFJZQSOLPXUBDT-AATRIKPKSA-N 0.000 description 2
- MJGKHGGVDVWINF-UHFFFAOYSA-N methyl 3-[8-[[cyclopropyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]quinolin-6-yl]prop-2-enoate Chemical compound C=12N=CC=CC2=CC(C=CC(=O)OC)=CC=1CN(C(=O)OC(C)(C)C)C1CC1 MJGKHGGVDVWINF-UHFFFAOYSA-N 0.000 description 2
- WYORXTKXJIADNG-UHFFFAOYSA-N methyl 3-[8-[[cyclopropyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]quinolin-6-yl]propanoate Chemical compound C=12N=CC=CC2=CC(CCC(=O)OC)=CC=1CN(C(=O)OC(C)(C)C)C1CC1 WYORXTKXJIADNG-UHFFFAOYSA-N 0.000 description 2
- FLKOEIWVAQTTCS-UHFFFAOYSA-N methyl 3-bromo-5-(3-hydroxypropyl)-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(CCCO)=C1 FLKOEIWVAQTTCS-UHFFFAOYSA-N 0.000 description 2
- CKJCZPSTEHWVIL-UHFFFAOYSA-N methyl 3-bromo-5-(3-iodopropyl)-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(CCCI)=C1 CKJCZPSTEHWVIL-UHFFFAOYSA-N 0.000 description 2
- DAMSKWOIBILOHK-UHFFFAOYSA-N methyl 3-bromo-5-(hydroxymethyl)-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(CO)=C1 DAMSKWOIBILOHK-UHFFFAOYSA-N 0.000 description 2
- VUHSUFWGVPFARG-UHFFFAOYSA-N methyl 3-bromo-5-(iodomethyl)-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(CI)=C1 VUHSUFWGVPFARG-UHFFFAOYSA-N 0.000 description 2
- KKZWDDUFAQHPOR-UHFFFAOYSA-N methyl 3-bromo-5-[(3-fluorophenyl)methyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(CC=2C=C(F)C=CC=2)=C1 KKZWDDUFAQHPOR-UHFFFAOYSA-N 0.000 description 2
- PJLVEJDFGDNYAA-UHFFFAOYSA-N methyl 3-bromo-5-[3-(difluoromethoxy)propyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(CCCOC(F)F)=C1 PJLVEJDFGDNYAA-UHFFFAOYSA-N 0.000 description 2
- YIEMWQJHQKHJOW-UHFFFAOYSA-N methyl 3-bromo-5-formyl-4-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(C)C(C=O)=C1 YIEMWQJHQKHJOW-UHFFFAOYSA-N 0.000 description 2
- SDCWDOMMQAIYON-UHFFFAOYSA-N methyl 3-ethenylnaphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC(C=C)=CC2=C1 SDCWDOMMQAIYON-UHFFFAOYSA-N 0.000 description 2
- GZXGMNZAFRTCPF-UHFFFAOYSA-N methyl 5-(3-methoxypropyl)-2-methylsulfanylbenzoate Chemical compound COCCCC1=CC=C(SC)C(C(=O)OC)=C1 GZXGMNZAFRTCPF-UHFFFAOYSA-N 0.000 description 2
- AUJZLQVDLUTYLJ-UHFFFAOYSA-N methyl 5-bromo-2-methylsulfanylbenzoate Chemical compound COC(=O)C1=CC(Br)=CC=C1SC AUJZLQVDLUTYLJ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- LRVXZNIDCLGYDJ-UHFFFAOYSA-N n-[2-(4-formylnaphthalen-2-yl)ethyl]acetamide Chemical compound C1=CC=CC2=CC(CCNC(=O)C)=CC(C=O)=C21 LRVXZNIDCLGYDJ-UHFFFAOYSA-N 0.000 description 2
- SPNMLUWCUKIEFN-UHFFFAOYSA-N n-[2-[4-(hydroxymethyl)naphthalen-2-yl]ethyl]acetamide Chemical compound C1=CC=CC2=CC(CCNC(=O)C)=CC(CO)=C21 SPNMLUWCUKIEFN-UHFFFAOYSA-N 0.000 description 2
- XHTXJLUGRORKQG-UHFFFAOYSA-N n-[3-(3-formylindol-1-yl)propyl]acetamide Chemical compound C1=CC=C2N(CCCNC(=O)C)C=C(C=O)C2=C1 XHTXJLUGRORKQG-UHFFFAOYSA-N 0.000 description 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000005949 ozonolysis reaction Methods 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- 229910001958 silver carbonate Inorganic materials 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLXIMHJAGCFUEA-RRPNLBNLSA-N tert-butyl (3S,4R)-3-[[3-bromo-5-(3-methoxypropyl)phenyl]methyl-cyclopropylcarbamoyl]-4-(1-methyl-2-oxopyridin-4-yl)piperidine-1-carboxylate Chemical compound BrC=1C=C(CN(C(=O)[C@@H]2CN(CC[C@H]2C2=CC(N(C=C2)C)=O)C(=O)OC(C)(C)C)C2CC2)C=C(C=1)CCCOC XLXIMHJAGCFUEA-RRPNLBNLSA-N 0.000 description 2
- XMCNGSZJNOHFGW-LEWJYISDSA-N tert-butyl (3S,4R)-3-[cyclopropyl-[(2,3-dichlorophenyl)methyl]carbamoyl]-4-(1-methyl-2-oxopyridin-4-yl)piperidine-1-carboxylate Chemical compound C1(CC1)N(C(=O)[C@@H]1CN(CC[C@H]1C1=CC(N(C=C1)C)=O)C(=O)OC(C)(C)C)CC1=C(C(=CC=C1)Cl)Cl XMCNGSZJNOHFGW-LEWJYISDSA-N 0.000 description 2
- WBKFPCOCWIOSOZ-XDFJSJKPSA-N tert-butyl (3S,4R)-3-[cyclopropyl-[[3-(2-methoxyethoxy)-5-(3-methoxypropyl)phenyl]methyl]carbamoyl]-4-(1,2,3-trimethyl-6-oxopyridin-4-yl)piperidine-1-carboxylate Chemical compound C1(CC1)N(C(=O)[C@@H]1CN(CC[C@H]1C1=CC(N(C(=C1C)C)C)=O)C(=O)OC(C)(C)C)CC1=CC(=CC(=C1)CCCOC)OCCOC WBKFPCOCWIOSOZ-XDFJSJKPSA-N 0.000 description 2
- OLYYEPZPQRYPCS-IOWSJCHKSA-N tert-butyl (3S,4R)-3-[cyclopropyl-[[3-(2-methoxyethoxy)-5-(3-methoxypropyl)phenyl]methyl]carbamoyl]-4-(1-ethyl-2-oxopyridin-4-yl)piperidine-1-carboxylate Chemical compound C1(CC1)N(C(=O)[C@@H]1CN(CC[C@H]1C1=CC(N(C=C1)CC)=O)C(=O)OC(C)(C)C)CC1=CC(=CC(=C1)CCCOC)OCCOC OLYYEPZPQRYPCS-IOWSJCHKSA-N 0.000 description 2
- IRZOJOMCROZDIE-UHFFFAOYSA-N tert-butyl N-[3-(3-formylindol-1-yl)propyl]carbamate Chemical compound C(C)(C)(C)OC(NCCCN1C=C(C2=CC=CC=C12)C=O)=O IRZOJOMCROZDIE-UHFFFAOYSA-N 0.000 description 2
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 2
- RCFHIFKSFYAJJM-UHFFFAOYSA-N tert-butyl n-[(3-bromo-5-formyl-4-methylphenyl)methyl]-n-cyclopropylcarbamate Chemical compound C1=C(C=O)C(C)=C(Br)C=C1CN(C(=O)OC(C)(C)C)C1CC1 RCFHIFKSFYAJJM-UHFFFAOYSA-N 0.000 description 2
- ZENKADQMRPNYRE-UHFFFAOYSA-N tert-butyl n-[(3-bromo-5-formylphenyl)methyl]-n-cyclopropylcarbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(Br)=CC(C=O)=C1 ZENKADQMRPNYRE-UHFFFAOYSA-N 0.000 description 2
- BQKWCKLCUQHQHY-UHFFFAOYSA-N tert-butyl n-[[3,5-bis(3-methoxypropyl)phenyl]methyl]-n-cyclopropylcarbamate Chemical compound COCCCC1=CC(CCCOC)=CC(CN(C2CC2)C(=O)OC(C)(C)C)=C1 BQKWCKLCUQHQHY-UHFFFAOYSA-N 0.000 description 2
- XMLXVKZMFJTTHQ-CDJQDVQCSA-N tert-butyl n-[[3,5-bis[(e)-3-methoxyprop-1-enyl]phenyl]methyl]-n-cyclopropylcarbamate Chemical compound COC/C=C/C1=CC(/C=C/COC)=CC(CN(C2CC2)C(=O)OC(C)(C)C)=C1 XMLXVKZMFJTTHQ-CDJQDVQCSA-N 0.000 description 2
- TYPQZTXVAXYBRB-UHFFFAOYSA-N tert-butyl n-[[3-bromo-5-(3-fluorobenzoyl)-4-methylphenyl]methyl]-n-cyclopropylcarbamate Chemical compound C1=C(C(=O)C=2C=C(F)C=CC=2)C(C)=C(Br)C=C1CN(C(=O)OC(C)(C)C)C1CC1 TYPQZTXVAXYBRB-UHFFFAOYSA-N 0.000 description 2
- JIQMPVKGRJVOFQ-VOTSOKGWSA-N tert-butyl n-[[3-bromo-5-[(e)-3-methoxyprop-1-enyl]-4-methylphenyl]methyl]-n-cyclopropylcarbamate Chemical compound BrC1=C(C)C(/C=C/COC)=CC(CN(C2CC2)C(=O)OC(C)(C)C)=C1 JIQMPVKGRJVOFQ-VOTSOKGWSA-N 0.000 description 2
- WXXMVVDDKJCAAX-UHFFFAOYSA-N tert-butyl n-[[5-(2-aminoethyl)-2,3-dichlorophenyl]methyl]-n-cyclopropylcarbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(CCN)=CC(Cl)=C1Cl WXXMVVDDKJCAAX-UHFFFAOYSA-N 0.000 description 2
- SBVAQRHUITZOAL-UHFFFAOYSA-N tert-butyl n-[[6-(2-cyanoethenyl)quinolin-8-yl]methyl]-n-cyclopropylcarbamate Chemical compound C=1C(C=CC#N)=CC2=CC=CN=C2C=1CN(C(=O)OC(C)(C)C)C1CC1 SBVAQRHUITZOAL-UHFFFAOYSA-N 0.000 description 2
- JAWRYUIHKHXQPH-UHFFFAOYSA-N tert-butyl n-[[6-[[tert-butyl(dimethyl)silyl]oxymethyl]quinolin-8-yl]methyl]-n-cyclopropylcarbamate Chemical compound C=1C(CO[Si](C)(C)C(C)(C)C)=CC2=CC=CN=C2C=1CN(C(=O)OC(C)(C)C)C1CC1 JAWRYUIHKHXQPH-UHFFFAOYSA-N 0.000 description 2
- ZLCGYWDOIIICTM-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[(2,3-dichloro-5-ethenylphenyl)methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(C=C)=CC(Cl)=C1Cl ZLCGYWDOIIICTM-UHFFFAOYSA-N 0.000 description 2
- SHVZPEJNUIFQHY-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[(2,3-dichloro-5-formylphenyl)methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(C=O)=CC(Cl)=C1Cl SHVZPEJNUIFQHY-UHFFFAOYSA-N 0.000 description 2
- YGBLYEGDKRTXOE-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-(2-hydroxyethyl)phenyl]methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(CCO)=CC(Cl)=C1Cl YGBLYEGDKRTXOE-UHFFFAOYSA-N 0.000 description 2
- PBGGVCCWXCDIEN-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-(2-oxoethyl)phenyl]methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(CC=O)=CC(Cl)=C1Cl PBGGVCCWXCDIEN-UHFFFAOYSA-N 0.000 description 2
- OZHGUYWVLHIPKD-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-(cyanomethyl)phenyl]methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(CC#N)=CC(Cl)=C1Cl OZHGUYWVLHIPKD-UHFFFAOYSA-N 0.000 description 2
- MIQHILZLGPBXQF-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-(hydroxymethyl)phenyl]methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(CO)=CC(Cl)=C1Cl MIQHILZLGPBXQF-UHFFFAOYSA-N 0.000 description 2
- MIBKLJSSQMSYHG-SNAWJCMRSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-[(e)-3-cyanoprop-2-enyl]phenyl]methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(C\C=C\C#N)=CC(Cl)=C1Cl MIBKLJSSQMSYHG-SNAWJCMRSA-N 0.000 description 2
- HGPFPIZJIIHKBA-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-[2-(methoxycarbonylamino)ethyl]phenyl]methyl]carbamate Chemical compound COC(=O)NCCC1=CC(Cl)=C(Cl)C(CN(C2CC2)C(=O)OC(C)(C)C)=C1 HGPFPIZJIIHKBA-UHFFFAOYSA-N 0.000 description 2
- FQNLHZAQNOSAQB-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[3-(3-methoxypropyl)-5-methylphenyl]methyl]carbamate Chemical compound COCCCC1=CC(C)=CC(CN(C2CC2)C(=O)OC(C)(C)C)=C1 FQNLHZAQNOSAQB-UHFFFAOYSA-N 0.000 description 2
- RNQQYRZDXYSSFT-AATRIKPKSA-N tert-butyl n-cyclopropyl-n-[[3-formyl-5-[(e)-3-methoxyprop-1-enyl]phenyl]methyl]carbamate Chemical compound O=CC1=CC(/C=C/COC)=CC(CN(C2CC2)C(=O)OC(C)(C)C)=C1 RNQQYRZDXYSSFT-AATRIKPKSA-N 0.000 description 2
- XXBSRQAGLCSEHH-VOTSOKGWSA-N tert-butyl n-cyclopropyl-n-[[5-[(e)-3-methoxyprop-1-enyl]-2-methylphenyl]methyl]carbamate Chemical compound COC\C=C\C1=CC=C(C)C(CN(C2CC2)C(=O)OC(C)(C)C)=C1 XXBSRQAGLCSEHH-VOTSOKGWSA-N 0.000 description 2
- PFYZJPQIBNKHDF-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[6-(3-hydroxypropyl)quinolin-8-yl]methyl]carbamate Chemical compound C=1C(CCCO)=CC2=CC=CN=C2C=1CN(C(=O)OC(C)(C)C)C1CC1 PFYZJPQIBNKHDF-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- IOWGHQGLUMEZKG-UHFFFAOYSA-N (2-bromophenyl)methanol Chemical compound OCC1=CC=CC=C1Br IOWGHQGLUMEZKG-UHFFFAOYSA-N 0.000 description 1
- IDXLUNCVVBZUEN-UHFFFAOYSA-N (3-formyl-5-methylphenyl)boronic acid Chemical compound CC1=CC(C=O)=CC(B(O)O)=C1 IDXLUNCVVBZUEN-UHFFFAOYSA-N 0.000 description 1
- VKNSVHKMSFFTLG-GXTWGEPZSA-N (3s,4r)-4-[5-(methoxymethoxy)-1-methyl-2-oxopyridin-4-yl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound COCOC1=CN(C)C(=O)C=C1[C@H]1[C@H](C(O)=O)CN(C(=O)OC(C)(C)C)CC1 VKNSVHKMSFFTLG-GXTWGEPZSA-N 0.000 description 1
- NOZRXTLPXGFTGF-UHFFFAOYSA-N (5-bromo-2,3-dichlorophenyl)methoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(Br)=CC(Cl)=C1Cl NOZRXTLPXGFTGF-UHFFFAOYSA-N 0.000 description 1
- VCGWKCCFTWRBNO-UHFFFAOYSA-N (8-bromoquinolin-6-yl)methoxy-tert-butyl-dimethylsilane Chemical compound N1=CC=CC2=CC(CO[Si](C)(C)C(C)(C)C)=CC(Br)=C21 VCGWKCCFTWRBNO-UHFFFAOYSA-N 0.000 description 1
- 125000001272 (C1-C4)-alkylene-phenyl group Chemical group 0.000 description 1
- 125000006726 (C1-C5) alkenyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- HCBFQHMXNKGYLU-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-(iodomethyl)propane Chemical compound FC(F)(F)C(CI)C(F)(F)F HCBFQHMXNKGYLU-UHFFFAOYSA-N 0.000 description 1
- OFNXSUANJLHGQN-UHFFFAOYSA-N 1,3-dibromo-5-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(Br)=CC(Br)=C1 OFNXSUANJLHGQN-UHFFFAOYSA-N 0.000 description 1
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 1
- LZIYAIRGDHSVED-UHFFFAOYSA-N 1-(bromomethyl)-3-chlorobenzene Chemical compound ClC1=CC=CC(CBr)=C1 LZIYAIRGDHSVED-UHFFFAOYSA-N 0.000 description 1
- FWLWTILKTABGKQ-UHFFFAOYSA-N 1-(bromomethyl)-3-methylbenzene Chemical compound CC1=CC=CC(CBr)=C1 FWLWTILKTABGKQ-UHFFFAOYSA-N 0.000 description 1
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- ATNLHYKLMMPXFP-UHFFFAOYSA-N 1-(naphthalen-2-ylmethyl)cyclopropan-1-amine Chemical compound C=1C=C2C=CC=CC2=CC=1CC1(N)CC1 ATNLHYKLMMPXFP-UHFFFAOYSA-N 0.000 description 1
- AVLICCVBQLBYTQ-DOTOQJQBSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-(1,2,3-trimethyl-6-oxopyridin-4-yl)piperidine-1,3-dicarboxylate Chemical compound CN1C(C=C(C(=C1C)C)[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC)=O AVLICCVBQLBYTQ-DOTOQJQBSA-N 0.000 description 1
- SBMZHKCSNPVACU-JKSUJKDBSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-(1-ethyl-2-oxopyridin-4-yl)piperidine-1,3-dicarboxylate Chemical compound C(C)N1C(C=C(C=C1)[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC)=O SBMZHKCSNPVACU-JKSUJKDBSA-N 0.000 description 1
- XMAOJIOXAJEEFZ-LSDHHAIUSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-(1-methyl-2-oxopyridin-4-yl)piperidine-1,3-dicarboxylate Chemical compound CN1C(C=C(C=C1)[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC)=O XMAOJIOXAJEEFZ-LSDHHAIUSA-N 0.000 description 1
- RMEVUIZJJBANOW-GOEBONIOSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-[3-(methoxymethoxy)-1-oxidopyridin-1-ium-4-yl]piperidine-1,3-dicarboxylate Chemical compound COCOC=1C=[N+](C=CC=1[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC)[O-] RMEVUIZJJBANOW-GOEBONIOSA-N 0.000 description 1
- CIBSVRHGZMOOBM-GOEBONIOSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-[5-(methoxymethoxy)-1-methyl-2-oxopyridin-4-yl]piperidine-1,3-dicarboxylate Chemical compound CN1C(C=C(C(=C1)OCOC)[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC)=O CIBSVRHGZMOOBM-GOEBONIOSA-N 0.000 description 1
- VVZPKPZDOKXWCN-LSDHHAIUSA-N 1-O-tert-butyl 3-O-ethyl (3S,4R)-4-pyridin-4-ylpiperidine-1,3-dicarboxylate Chemical compound N1=CC=C(C=C1)[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C(=O)OCC VVZPKPZDOKXWCN-LSDHHAIUSA-N 0.000 description 1
- IXDNPBBWQOAMHU-UHFFFAOYSA-N 1-[(2-bromophenyl)methyl]cyclopropan-1-amine Chemical compound C=1C=CC=C(Br)C=1CC1(N)CC1 IXDNPBBWQOAMHU-UHFFFAOYSA-N 0.000 description 1
- HYOXKVCAZMWPCE-UHFFFAOYSA-N 1-[(5-chloro-2-methylphenyl)methyl]cyclopropan-1-amine Chemical compound CC1=CC=C(Cl)C=C1CC1(N)CC1 HYOXKVCAZMWPCE-UHFFFAOYSA-N 0.000 description 1
- JSPZFYYHSXZBPY-UHFFFAOYSA-N 1-[3-[(cyclopropylamino)methyl]-5-(3-methoxypropyl)phenyl]ethanone Chemical compound CC(=O)C1=CC(CCCOC)=CC(CNC2CC2)=C1 JSPZFYYHSXZBPY-UHFFFAOYSA-N 0.000 description 1
- FFSCNVAJOFWGEH-UHFFFAOYSA-N 1-[3-bromo-5-[(cyclopropylamino)methyl]-2-methylphenyl]-2-(3-fluorophenyl)ethanone Chemical compound C1=C(C(=O)CC=2C=C(F)C=CC=2)C(C)=C(Br)C=C1CNC1CC1 FFSCNVAJOFWGEH-UHFFFAOYSA-N 0.000 description 1
- YCBHSKGABMLPOI-UHFFFAOYSA-N 1-benzyl-3-[(cyclopropylamino)methyl]indole-4-carbonitrile Chemical compound C1=C(CNC2CC2)C=2C(C#N)=CC=CC=2N1CC1=CC=CC=C1 YCBHSKGABMLPOI-UHFFFAOYSA-N 0.000 description 1
- JOZWPJGRGUOZGY-UHFFFAOYSA-N 1-bromo-3-ethoxypropane Chemical compound CCOCCCBr JOZWPJGRGUOZGY-UHFFFAOYSA-N 0.000 description 1
- DFPCDBCOJBWKML-UHFFFAOYSA-N 1-o-tert-butyl 5-o-ethyl 4-(2-methoxypyridin-4-yl)-3,6-dihydro-2h-pyridine-1,5-dicarboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC(C(=O)OCC)=C1C1=CC=NC(OC)=C1 DFPCDBCOJBWKML-UHFFFAOYSA-N 0.000 description 1
- QBSFHOMPPMKXAV-UHFFFAOYSA-N 1-o-tert-butyl 5-o-ethyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1,5-dicarboxylate Chemical compound CCOC(=O)C1=C(OS(=O)(=O)C(F)(F)F)CCN(C(=O)OC(C)(C)C)C1 QBSFHOMPPMKXAV-UHFFFAOYSA-N 0.000 description 1
- VUEWYZJJYGPJDC-UHFFFAOYSA-N 1-oxaspiro[2.5]octane Chemical compound C1OC11CCCCC1 VUEWYZJJYGPJDC-UHFFFAOYSA-N 0.000 description 1
- CEUFGDDOMXCXFW-UHFFFAOYSA-N 1h-indole-4-carbonitrile Chemical compound N#CC1=CC=CC2=C1C=CN2 CEUFGDDOMXCXFW-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- VYDQUABHDFWIIX-UHFFFAOYSA-N 2,2-difluoro-2-fluorosulfonylacetic acid Chemical compound OC(=O)C(F)(F)S(F)(=O)=O VYDQUABHDFWIIX-UHFFFAOYSA-N 0.000 description 1
- LLMLNAVBOAMOEE-UHFFFAOYSA-N 2,3-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1Cl LLMLNAVBOAMOEE-UHFFFAOYSA-N 0.000 description 1
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- OPQCZUJEDILWGS-UHFFFAOYSA-N 2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4,5-dichlorophenyl]ethanamine Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(CCN)=CC(Cl)=C1Cl OPQCZUJEDILWGS-UHFFFAOYSA-N 0.000 description 1
- GTAQZCXKKMMPKV-UHFFFAOYSA-N 2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4,5-dichlorophenyl]ethyl methanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(CCOS(C)(=O)=O)=CC(Cl)=C1Cl GTAQZCXKKMMPKV-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- CYIWQARPPLMHJF-UHFFFAOYSA-N 2-cyclopropyl-5-(3-methoxyprop-1-ynyl)-4-methylbenzamide Chemical compound C1(CC1)C1=C(C(=O)N)C=C(C(=C1)C)C#CCOC CYIWQARPPLMHJF-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- NJFNLMDSRHQQNR-UHFFFAOYSA-N 3,5-dibromo-2-methoxybenzaldehyde Chemical compound COC1=C(Br)C=C(Br)C=C1C=O NJFNLMDSRHQQNR-UHFFFAOYSA-N 0.000 description 1
- SJCBUASMFSRONS-UHFFFAOYSA-N 3,5-dibromo-4-methylbenzoic acid Chemical compound CC1=C(Br)C=C(C(O)=O)C=C1Br SJCBUASMFSRONS-UHFFFAOYSA-N 0.000 description 1
- SFTFNJZWZHASAQ-UHFFFAOYSA-N 3,5-dibromobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC(Br)=C1 SFTFNJZWZHASAQ-UHFFFAOYSA-N 0.000 description 1
- PZFMWYNHJFZBPO-UHFFFAOYSA-N 3,5-dibromophenol Chemical compound OC1=CC(Br)=CC(Br)=C1 PZFMWYNHJFZBPO-UHFFFAOYSA-N 0.000 description 1
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 1
- MMDFTYGZZLJQER-UHFFFAOYSA-N 3-(trifluoromethylsulfanyl)benzaldehyde Chemical compound FC(F)(F)SC1=CC=CC(C=O)=C1 MMDFTYGZZLJQER-UHFFFAOYSA-N 0.000 description 1
- KVTUKAQUSFRAAF-UHFFFAOYSA-N 3-[(cyclopropylamino)methyl]-5-(3-methoxypropyl)phenol Chemical compound COCCCC1=CC(O)=CC(CNC2CC2)=C1 KVTUKAQUSFRAAF-UHFFFAOYSA-N 0.000 description 1
- FUTXOLVIKQAEDR-UHFFFAOYSA-N 3-[3,4-dichloro-5-[(cyclopropylamino)methyl]phenyl]propanenitrile Chemical compound ClC1=CC(CCC#N)=CC(CNC2CC2)=C1Cl FUTXOLVIKQAEDR-UHFFFAOYSA-N 0.000 description 1
- ZSLNYHPUKVZRGM-UHFFFAOYSA-N 3-[3-bromo-5-[(cyclopropylamino)methyl]-2-methylphenyl]propan-1-ol Chemical compound C1=C(CCCO)C(C)=C(Br)C=C1CNC1CC1 ZSLNYHPUKVZRGM-UHFFFAOYSA-N 0.000 description 1
- AWAWMMQSFRJYQC-UHFFFAOYSA-N 3-[8-[(cyclopropylamino)methyl]quinolin-6-yl]propanenitrile Chemical compound C=12N=CC=CC2=CC(CCC#N)=CC=1CNC1CC1 AWAWMMQSFRJYQC-UHFFFAOYSA-N 0.000 description 1
- PGYLSHRCSCQCOR-UHFFFAOYSA-N 3-[[3-[(cyclopropylamino)methyl]indol-1-yl]methyl]benzonitrile Chemical compound N#CC1=CC=CC(CN2C3=CC=CC=C3C(CNC3CC3)=C2)=C1 PGYLSHRCSCQCOR-UHFFFAOYSA-N 0.000 description 1
- ZFJOMUKPDWNRFI-UHFFFAOYSA-N 3-bromo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1Br ZFJOMUKPDWNRFI-UHFFFAOYSA-N 0.000 description 1
- JGMGDYUVFBBCEQ-UHFFFAOYSA-N 3-bromo-5-chlorobenzaldehyde Chemical compound ClC1=CC(Br)=CC(C=O)=C1 JGMGDYUVFBBCEQ-UHFFFAOYSA-N 0.000 description 1
- LYVFIZDTOOBDPB-UHFFFAOYSA-N 3-bromo-5-iodo-4-methylbenzoic acid Chemical compound CC1=C(Br)C=C(C(O)=O)C=C1I LYVFIZDTOOBDPB-UHFFFAOYSA-N 0.000 description 1
- MKJBJYCBKXPQSY-UHFFFAOYSA-N 3-bromo-5-iodobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC(I)=C1 MKJBJYCBKXPQSY-UHFFFAOYSA-N 0.000 description 1
- JNETYVLEGPSOFY-UHFFFAOYSA-N 3-bromopyrrolidine-2,5-dione Chemical compound BrC1CC(=O)NC1=O JNETYVLEGPSOFY-UHFFFAOYSA-N 0.000 description 1
- UBMFGSPAKDXXHX-NSCUHMNNSA-N 3-hydroxy-5-[(e)-3-methoxyprop-1-enyl]benzaldehyde Chemical compound COC\C=C\C1=CC(O)=CC(C=O)=C1 UBMFGSPAKDXXHX-NSCUHMNNSA-N 0.000 description 1
- YACFFSVYSPMSGS-UHFFFAOYSA-N 3-methoxyprop-1-yne Chemical compound COCC#C YACFFSVYSPMSGS-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- VUTMZWOLPWRQDB-UHFFFAOYSA-N 4-(1-methyl-2-oxopyridin-4-yl)piperidine-1-carboxylic acid Chemical compound O=C1N(C)C=CC(C2CCN(CC2)C(O)=O)=C1 VUTMZWOLPWRQDB-UHFFFAOYSA-N 0.000 description 1
- VAJUUDUWDNCECT-UHFFFAOYSA-N 4-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=NC=C1 VAJUUDUWDNCECT-UHFFFAOYSA-N 0.000 description 1
- ITIMYFQTPXIPKP-UHFFFAOYSA-N 4-[3,4-dichloro-5-[(cyclopropylamino)methyl]phenyl]butanenitrile Chemical compound ClC1=CC(CCCC#N)=CC(CNC2CC2)=C1Cl ITIMYFQTPXIPKP-UHFFFAOYSA-N 0.000 description 1
- CURFHMOIVPJNGH-UHFFFAOYSA-N 4-[3-[(cyclopropylamino)methyl]-4,5-difluorophenyl]butanenitrile Chemical compound FC1=CC(CCCC#N)=CC(CNC2CC2)=C1F CURFHMOIVPJNGH-UHFFFAOYSA-N 0.000 description 1
- BUWXVXONESGFRO-UHFFFAOYSA-N 4-bromo-2,3-dimethyl-6-phenylmethoxypyridine Chemical compound BrC1=C(C)C(C)=NC(OCC=2C=CC=CC=2)=C1 BUWXVXONESGFRO-UHFFFAOYSA-N 0.000 description 1
- ONHMWUXYIFULDO-UHFFFAOYSA-N 4-bromo-2-chloropyridine Chemical compound ClC1=CC(Br)=CC=N1 ONHMWUXYIFULDO-UHFFFAOYSA-N 0.000 description 1
- PTPTZLXZHPPVKG-UHFFFAOYSA-N 4-bromo-2-fluoropyridine Chemical compound FC1=CC(Br)=CC=N1 PTPTZLXZHPPVKG-UHFFFAOYSA-N 0.000 description 1
- ZBTZIRNIUHLSSJ-UHFFFAOYSA-N 4-bromo-2-phenylmethoxypyridine Chemical compound BrC1=CC=NC(OCC=2C=CC=CC=2)=C1 ZBTZIRNIUHLSSJ-UHFFFAOYSA-N 0.000 description 1
- REKJIRGJMRZCBX-UHFFFAOYSA-N 4-bromo-5,6-dimethyl-1h-pyridin-2-one Chemical compound CC=1NC(=O)C=C(Br)C=1C REKJIRGJMRZCBX-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- XFTWRMVWQKCYOV-UHFFFAOYSA-N 4-iodo-3-(methoxymethoxy)pyridine Chemical compound COCOC1=CN=CC=C1I XFTWRMVWQKCYOV-UHFFFAOYSA-N 0.000 description 1
- UTVSKIJSZDQKQQ-UHFFFAOYSA-N 5-[(cyclopropylamino)methyl]-1,3-bis(3-methoxypropyl)pyrimidine-2,4-dione Chemical compound O=C1N(CCCOC)C(=O)N(CCCOC)C=C1CNC1CC1 UTVSKIJSZDQKQQ-UHFFFAOYSA-N 0.000 description 1
- UINIBOQGXIFOQN-UHFFFAOYSA-N 5-bromo-2-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1S UINIBOQGXIFOQN-UHFFFAOYSA-N 0.000 description 1
- CSAPESWNZDOAFU-UHFFFAOYSA-N 5-chloro-2-methylbenzoic acid Chemical compound CC1=CC=C(Cl)C=C1C(O)=O CSAPESWNZDOAFU-UHFFFAOYSA-N 0.000 description 1
- YUAJKGBLPVLADK-UHFFFAOYSA-N 5-fluoro-1h-indole-3-carbaldehyde Chemical compound FC1=CC=C2NC=C(C=O)C2=C1 YUAJKGBLPVLADK-UHFFFAOYSA-N 0.000 description 1
- OHAMXGZMZZWRCA-UHFFFAOYSA-N 5-formyluracil Chemical compound OC1=NC=C(C=O)C(O)=N1 OHAMXGZMZZWRCA-UHFFFAOYSA-N 0.000 description 1
- MAWGHOPSCKCTPA-UHFFFAOYSA-N 6-bromo-1h-indole Chemical compound BrC1=CC=C2C=CNC2=C1 MAWGHOPSCKCTPA-UHFFFAOYSA-N 0.000 description 1
- SEQHEDQNODAFIU-UHFFFAOYSA-N 6-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=C2CCC(=O)C2=C1 SEQHEDQNODAFIU-UHFFFAOYSA-N 0.000 description 1
- YGVDCGFUUUJCDF-UHFFFAOYSA-N 7-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(Br)=CC=C21 YGVDCGFUUUJCDF-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ULBKPOLZIAPNAO-UHFFFAOYSA-N C(C(C)C)[AlH]CC(C)C.ClCCl.N12CCCCCC2=NCCC1 Chemical compound C(C(C)C)[AlH]CC(C)C.ClCCl.N12CCCCCC2=NCCC1 ULBKPOLZIAPNAO-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- JWSKTHFFAZUNRZ-UHFFFAOYSA-N C1=NC=CC2=CC=CC(=C12)CN1CC(C(CC1)C1=CC(N(C=C1)C)=O)C(=O)N Chemical compound C1=NC=CC2=CC=CC(=C12)CN1CC(C(CC1)C1=CC(N(C=C1)C)=O)C(=O)N JWSKTHFFAZUNRZ-UHFFFAOYSA-N 0.000 description 1
- CSSVULFHHGITSW-UHFFFAOYSA-N CC(C)(C)[SiH](C)C.[Cl] Chemical compound CC(C)(C)[SiH](C)C.[Cl] CSSVULFHHGITSW-UHFFFAOYSA-N 0.000 description 1
- BLMRHBMQGYVZBO-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OCC=1C=C2C=CC=NC2=C(C1)CC1(CC1)N Chemical compound CC(C)(C)[Si](C)(C)OCC=1C=C2C=CC=NC2=C(C1)CC1(CC1)N BLMRHBMQGYVZBO-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- KMJSPCIDWJBVMQ-UHFFFAOYSA-N FC(C(=O)N)(F)F.[N] Chemical group FC(C(=O)N)(F)F.[N] KMJSPCIDWJBVMQ-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- UKGIRTGLZQEIEK-UHFFFAOYSA-M O1CCCC1.FC(C(=O)O)(F)F.[F-].C(CCC)[N+](CCCC)(CCCC)CCCC Chemical compound O1CCCC1.FC(C(=O)O)(F)F.[F-].C(CCC)[N+](CCCC)(CCCC)CCCC UKGIRTGLZQEIEK-UHFFFAOYSA-M 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- VJRITMATACIYAF-UHFFFAOYSA-N benzenesulfonohydrazide Chemical compound NNS(=O)(=O)C1=CC=CC=C1 VJRITMATACIYAF-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940068911 chloride hexahydrate Drugs 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YSSSPARMOAYJTE-UHFFFAOYSA-N dibenzo-18-crown-6 Chemical compound O1CCOCCOC2=CC=CC=C2OCCOCCOC2=CC=CC=C21 YSSSPARMOAYJTE-UHFFFAOYSA-N 0.000 description 1
- KVBKAPANDHPRDG-UHFFFAOYSA-N dibromotetrafluoroethane Chemical compound FC(F)(Br)C(F)(F)Br KVBKAPANDHPRDG-UHFFFAOYSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- WHOBZBLBTZHMGY-UHFFFAOYSA-N ditert-butyl(ethyl)phosphane Chemical compound CCP(C(C)(C)C)C(C)(C)C WHOBZBLBTZHMGY-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- YCAQOJIVZKBMQV-UHFFFAOYSA-N ethyl 1-(2,2,2-trifluoroacetyl)-4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-5-carboxylate Chemical compound CCOC(=O)C1=C(OS(=O)(=O)C(F)(F)F)CCN(C(=O)C(F)(F)F)C1 YCAQOJIVZKBMQV-UHFFFAOYSA-N 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000004806 hydroxypyridines Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- HORFVOWTVOJVAN-UHFFFAOYSA-N isoquinoline-1-carbaldehyde Chemical compound C1=CC=C2C(C=O)=NC=CC2=C1 HORFVOWTVOJVAN-UHFFFAOYSA-N 0.000 description 1
- ILRSABOCKMOFGW-UHFFFAOYSA-N isoquinoline-5-carbaldehyde Chemical compound N1=CC=C2C(C=O)=CC=CC2=C1 ILRSABOCKMOFGW-UHFFFAOYSA-N 0.000 description 1
- KPYBESJNSLIHRF-UHFFFAOYSA-N isoquinoline-8-carbaldehyde Chemical compound C1=NC=C2C(C=O)=CC=CC2=C1 KPYBESJNSLIHRF-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- LWLPYZUDBNFNAH-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CCC[CH2-] LWLPYZUDBNFNAH-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JBUWXXYLEJNOTG-UHFFFAOYSA-N methyl 4-[3,4-dichloro-5-[(cyclopropylamino)methyl]phenyl]butanoate Chemical compound COC(=O)CCCC1=CC(Cl)=C(Cl)C(CNC2CC2)=C1 JBUWXXYLEJNOTG-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- AZSFWYDHXVOVMC-UHFFFAOYSA-N n-(isoquinolin-1-ylmethyl)cyclopropanamine Chemical compound N=1C=CC2=CC=CC=C2C=1CNC1CC1 AZSFWYDHXVOVMC-UHFFFAOYSA-N 0.000 description 1
- SDWXTQCFTPNNKU-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-n',n'-bis[2-(pyridin-2-ylmethylamino)ethyl]ethane-1,2-diamine Chemical compound C=1C=CC=NC=1CNCCN(CCNCC=1N=CC=CC=1)CCNCC1=CC=CC=N1 SDWXTQCFTPNNKU-UHFFFAOYSA-N 0.000 description 1
- MROWANQIZXIVCI-UHFFFAOYSA-N n-[(1-butylindol-3-yl)methyl]cyclopropanamine Chemical compound C12=CC=CC=C2N(CCCC)C=C1CNC1CC1 MROWANQIZXIVCI-UHFFFAOYSA-N 0.000 description 1
- UZAISWJSDNVKQT-UHFFFAOYSA-N n-[(1-prop-2-enylindol-3-yl)methyl]cyclopropanamine Chemical compound C12=CC=CC=C2N(CC=C)C=C1CNC1CC1 UZAISWJSDNVKQT-UHFFFAOYSA-N 0.000 description 1
- XVQBMGKGTHOEBN-UHFFFAOYSA-N n-[2-(3,4-dichloro-5-formylphenyl)ethyl]propanamide Chemical compound CCC(=O)NCCC1=CC(Cl)=C(Cl)C(C=O)=C1 XVQBMGKGTHOEBN-UHFFFAOYSA-N 0.000 description 1
- IEJGXLYZGZSTSZ-UHFFFAOYSA-N n-[2-[3,4-dichloro-5-(hydroxymethyl)phenyl]ethyl]propanamide Chemical compound CCC(=O)NCCC1=CC(Cl)=C(Cl)C(CO)=C1 IEJGXLYZGZSTSZ-UHFFFAOYSA-N 0.000 description 1
- VVLFAUANEHDANX-UHFFFAOYSA-N n-[2-[3,4-dichloro-5-[(cyclopropylamino)methyl]phenyl]ethyl]propanamide Chemical compound CCC(=O)NCCC1=CC(Cl)=C(Cl)C(CNC2CC2)=C1 VVLFAUANEHDANX-UHFFFAOYSA-N 0.000 description 1
- AVZCYWCYNDXDRG-UHFFFAOYSA-N n-[2-[3-[(cyclopropylamino)methyl]indol-1-yl]ethyl]acetamide Chemical compound C12=CC=CC=C2N(CCNC(=O)C)C=C1CNC1CC1 AVZCYWCYNDXDRG-UHFFFAOYSA-N 0.000 description 1
- CMJQSIHVUGSRNF-UHFFFAOYSA-N n-[3-[3-[(cyclopropylamino)methyl]indol-1-yl]propyl]acetamide Chemical compound C12=CC=CC=C2N(CCCNC(=O)C)C=C1CNC1CC1 CMJQSIHVUGSRNF-UHFFFAOYSA-N 0.000 description 1
- COGMJOZXQWFTIO-UHFFFAOYSA-N n-[3-[3-[(cyclopropylamino)methyl]indol-1-yl]propyl]propanamide Chemical compound C12=CC=CC=C2N(CCCNC(=O)CC)C=C1CNC1CC1 COGMJOZXQWFTIO-UHFFFAOYSA-N 0.000 description 1
- SBZANQADSIUOIU-UHFFFAOYSA-N n-[[1-(2-methoxyethyl)indol-3-yl]methyl]cyclopropanamine Chemical compound C12=CC=CC=C2N(CCOC)C=C1CNC1CC1 SBZANQADSIUOIU-UHFFFAOYSA-N 0.000 description 1
- YAZBIWAWESAWKU-UHFFFAOYSA-N n-[[1-(pyridin-2-ylmethyl)indol-3-yl]methyl]cyclopropanamine Chemical compound C=1N(CC=2N=CC=CC=2)C2=CC=CC=C2C=1CNC1CC1 YAZBIWAWESAWKU-UHFFFAOYSA-N 0.000 description 1
- WHSLQRSBKBPUQM-UHFFFAOYSA-N n-[[1-(pyridin-3-ylmethyl)indol-3-yl]methyl]cyclopropanamine Chemical compound C=1N(CC=2C=NC=CC=2)C2=CC=CC=C2C=1CNC1CC1 WHSLQRSBKBPUQM-UHFFFAOYSA-N 0.000 description 1
- OQUOZTONHPAIPU-UHFFFAOYSA-N n-[[1-(pyridin-4-ylmethyl)indol-3-yl]methyl]cyclopropanamine Chemical compound C=1N(CC=2C=CN=CC=2)C2=CC=CC=C2C=1CNC1CC1 OQUOZTONHPAIPU-UHFFFAOYSA-N 0.000 description 1
- PCOQZHKMMRCBNW-UHFFFAOYSA-N n-[[3,5-bis(3-methoxypropyl)phenyl]methyl]cyclopropanamine Chemical compound COCCCC1=CC(CCCOC)=CC(CNC2CC2)=C1 PCOQZHKMMRCBNW-UHFFFAOYSA-N 0.000 description 1
- GOLKLQMKXZCGGD-UHFFFAOYSA-N n-[[3-bromo-5-(3-methoxypropyl)-4-methylphenyl]methyl]cyclopropanamine Chemical compound BrC1=C(C)C(CCCOC)=CC(CNC2CC2)=C1 GOLKLQMKXZCGGD-UHFFFAOYSA-N 0.000 description 1
- MXNWZGMQPCNVQB-UHFFFAOYSA-N n-[[3-bromo-5-(3-methoxypropyl)-4-methylphenyl]methyl]cyclopropanamine;methanesulfonic acid Chemical compound CS(O)(=O)=O.BrC1=C(C)C(CCCOC)=CC(CNC2CC2)=C1 MXNWZGMQPCNVQB-UHFFFAOYSA-N 0.000 description 1
- UGCYTKOXHFLQJF-UHFFFAOYSA-N n-[[3-bromo-5-[3-(difluoromethoxy)propyl]-4-methylphenyl]methyl]cyclopropanamine Chemical compound C1=C(CCCOC(F)F)C(C)=C(Br)C=C1CNC1CC1 UGCYTKOXHFLQJF-UHFFFAOYSA-N 0.000 description 1
- ZJDJNWROGMJVAV-UHFFFAOYSA-N n-[[3-chloro-5-(3-methoxypropyl)phenyl]methyl]cyclopropanamine Chemical compound COCCCC1=CC(Cl)=CC(CNC2CC2)=C1 ZJDJNWROGMJVAV-UHFFFAOYSA-N 0.000 description 1
- BRMIMMQPJVJVOL-NSCUHMNNSA-N n-[[3-chloro-5-[(e)-3-methoxyprop-1-enyl]phenyl]methyl]cyclopropanamine Chemical compound COC\C=C\C1=CC(Cl)=CC(CNC2CC2)=C1 BRMIMMQPJVJVOL-NSCUHMNNSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IASIJDXUZOLTAH-UHFFFAOYSA-N n-cyclopropylbenzamide Chemical compound C=1C=CC=CC=1C(=O)NC1CC1 IASIJDXUZOLTAH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001315 phosphanylidene group Chemical group [H]P=* 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- MHZDONKZSXBOGL-UHFFFAOYSA-N propyl dihydrogen phosphate Chemical compound CCCOP(O)(O)=O MHZDONKZSXBOGL-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- BNEVFKZLYCGDFG-UHFFFAOYSA-N quinoline-5-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=N1 BNEVFKZLYCGDFG-UHFFFAOYSA-N 0.000 description 1
- OVZQVGZERAFSPI-UHFFFAOYSA-N quinoline-8-carbaldehyde Chemical compound C1=CN=C2C(C=O)=CC=CC2=C1 OVZQVGZERAFSPI-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XUPJWRMTMRGIEB-LOSJGSFVSA-N tert-butyl (3S,4R)-3-[cyclopropyl-[[2,3-dichloro-5-(4-methoxy-4-oxobutyl)phenyl]methyl]carbamoyl]-4-(1-methyl-2-oxopyridin-4-yl)piperidine-1-carboxylate Chemical compound C1(CC1)N(C(=O)[C@@H]1CN(CC[C@H]1C1=CC(N(C=C1)C)=O)C(=O)OC(C)(C)C)CC1=C(C(=CC(=C1)CCCC(=O)OC)Cl)Cl XUPJWRMTMRGIEB-LOSJGSFVSA-N 0.000 description 1
- IOKGWQZQCNXXLD-UHFFFAOYSA-N tert-butyl n-(3-bromopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCBr IOKGWQZQCNXXLD-UHFFFAOYSA-N 0.000 description 1
- UAMUYTOKOPUMTK-UHFFFAOYSA-N tert-butyl n-[[6-(2-cyanoethyl)quinolin-8-yl]methyl]-n-cyclopropylcarbamate Chemical compound C=1C(CCC#N)=CC2=CC=CN=C2C=1CN(C(=O)OC(C)(C)C)C1CC1 UAMUYTOKOPUMTK-UHFFFAOYSA-N 0.000 description 1
- YSWVXPXPYDCQBA-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-(2-methoxyethyl)phenyl]methyl]carbamate Chemical compound COCCC1=CC(Cl)=C(Cl)C(CN(C2CC2)C(=O)OC(C)(C)C)=C1 YSWVXPXPYDCQBA-UHFFFAOYSA-N 0.000 description 1
- LIDXAAZRTXASAS-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[2,3-dichloro-5-(3-cyanopropyl)phenyl]methyl]carbamate Chemical compound C1CC1N(C(=O)OC(C)(C)C)CC1=CC(CCCC#N)=CC(Cl)=C1Cl LIDXAAZRTXASAS-UHFFFAOYSA-N 0.000 description 1
- NEZKPGPUKCQGLJ-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[5-(3-methoxypropyl)-2-methylphenyl]methyl]carbamate Chemical compound COCCCC1=CC=C(C)C(CN(C2CC2)C(=O)OC(C)(C)C)=C1 NEZKPGPUKCQGLJ-UHFFFAOYSA-N 0.000 description 1
- RJJGLBKVURCKSD-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[6-(3-methoxypropyl)quinolin-8-yl]methyl]carbamate Chemical compound C=12N=CC=CC2=CC(CCCOC)=CC=1CN(C(=O)OC(C)(C)C)C1CC1 RJJGLBKVURCKSD-UHFFFAOYSA-N 0.000 description 1
- HROCDXWUJPEWFX-UHFFFAOYSA-N tert-butyl n-cyclopropyl-n-[[6-(hydroxymethyl)quinolin-8-yl]methyl]carbamate Chemical compound C=1C(CO)=CC2=CC=CN=C2C=1CN(C(=O)OC(C)(C)C)C1CC1 HROCDXWUJPEWFX-UHFFFAOYSA-N 0.000 description 1
- PPGMOMOJRKJGQE-UHFFFAOYSA-N tert-butyl-[(2,3-dichloro-5-ethenylphenyl)methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(C=C)=CC(Cl)=C1Cl PPGMOMOJRKJGQE-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- XQKBFQXWZCFNFF-UHFFFAOYSA-K triiodosamarium Chemical compound I[Sm](I)I XQKBFQXWZCFNFF-UHFFFAOYSA-K 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 101150041325 vopp1 gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12652908P | 2008-05-05 | 2008-05-05 | |
| US18830308P | 2008-08-07 | 2008-08-07 | |
| PCT/CA2009/000611 WO2009135299A1 (en) | 2008-05-05 | 2009-05-04 | 3, 4 - substituted piperidine derivatives as renin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201071269A1 EA201071269A1 (ru) | 2011-06-30 |
| EA020853B1 true EA020853B1 (ru) | 2015-02-27 |
Family
ID=41264366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201071269A EA020853B1 (ru) | 2008-05-05 | 2009-05-04 | 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8889714B2 (enExample) |
| EP (1) | EP2274295B1 (enExample) |
| JP (3) | JP4790871B2 (enExample) |
| KR (2) | KR20130029116A (enExample) |
| CN (1) | CN102015682B (enExample) |
| AU (1) | AU2009243875B2 (enExample) |
| BR (1) | BRPI0912388A2 (enExample) |
| CA (1) | CA2722734C (enExample) |
| CO (1) | CO6311081A2 (enExample) |
| CR (1) | CR11809A (enExample) |
| DO (1) | DOP2010000329A (enExample) |
| EA (1) | EA020853B1 (enExample) |
| ES (1) | ES2548134T3 (enExample) |
| IL (1) | IL208467A (enExample) |
| MA (1) | MA32296B1 (enExample) |
| MX (1) | MX2010012067A (enExample) |
| MY (1) | MY152042A (enExample) |
| NI (1) | NI201000188A (enExample) |
| NZ (1) | NZ589019A (enExample) |
| PL (1) | PL2274295T3 (enExample) |
| SG (1) | SG192543A1 (enExample) |
| SV (1) | SV2010003723A (enExample) |
| WO (1) | WO2009135299A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| JP2012511514A (ja) * | 2008-12-10 | 2012-05-24 | メルク・カナダ・インコーポレイテツド | レニン阻害剤としての3,4−置換ピペリジン誘導体 |
| TWI622573B (zh) * | 2010-11-05 | 2018-05-01 | 拜耳知識產權公司 | 藉由亞胺氫化製備經取代n-(苄基)環丙胺之方法 |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| CN107602381B (zh) * | 2017-09-11 | 2021-03-16 | 陕西莱特光电材料股份有限公司 | 一种萘甲酸酯类衍生物及其制备方法 |
| CN108033876A (zh) * | 2017-12-20 | 2018-05-15 | 江汉大学 | 一种5-溴-2-氯苯甲醛的制备方法 |
| EP3887357A1 (en) | 2018-11-28 | 2021-10-06 | Basf Se | Pesticidal compounds |
| WO2021219513A1 (en) | 2020-04-28 | 2021-11-04 | Basf Se | Pesticidal compounds |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2570920A1 (en) * | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Piperidine derivatives as renin inhibitors |
| CA2587348A1 (en) * | 2004-12-30 | 2006-07-06 | Novartis Ag | Organic compounds |
| CA2590898A1 (en) * | 2005-01-14 | 2006-07-20 | Novartis Ag | 3,4,(5)-substituted tetrahvdropyridines |
| CA2598861A1 (en) * | 2005-03-09 | 2006-09-14 | Novartis Ag | Organic compounds |
| CA2609355A1 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Organic compounds |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| KR100384979B1 (ko) | 1995-09-07 | 2003-10-17 | 에프. 호프만-라 로슈 아게 | 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘 |
| US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| AU722480B2 (en) | 1996-11-01 | 2000-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| IT1295694B1 (it) * | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292426B1 (it) | 1997-06-27 | 1999-02-08 | Nicox Sa | Sali nitrati di ace-inibitori |
| WO2002032872A1 (fr) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| PL372141A1 (en) | 2002-04-29 | 2005-07-11 | Actelion Pharmaceuticals Ltd. | 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
| JP2005532371A (ja) | 2002-06-27 | 2005-10-27 | アクテリオン ファマシューティカルズ リミテッド | レニン阻害剤としての新規なテトラヒドロピリジン誘導体 |
| US20040204455A1 (en) | 2003-04-10 | 2004-10-14 | Cody Wayne Livingston | Piperidine derivative rennin inhibitors |
| US20060217371A1 (en) | 2003-04-28 | 2006-09-28 | Olivier Bezencon | Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors |
| BRPI0409881A (pt) | 2003-04-29 | 2006-05-23 | Actelion Pharmaceuticals Ltd | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
| AU2004234038A1 (en) | 2003-04-30 | 2004-11-11 | Actelion Pharmaceuticals Ltd. | Azabicyclononene derivatives |
| JP2006524657A (ja) | 2003-04-30 | 2006-11-02 | アクテリオン ファマシューティカルズ リミテッド | 新規トロパン誘導体 |
| AU2004233575A1 (en) | 2003-04-30 | 2004-11-11 | Actelion Pharmaceuticals Ltd | 9-azabicyclo'3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors |
| RU2005137571A (ru) | 2003-05-02 | 2006-05-10 | Актелион Фармасьютикалз Лтд. (Ch) | Новые производные диазабициклононена |
| TW200900399A (en) | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
| CN1863773A (zh) | 2003-10-09 | 2006-11-15 | 埃科特莱茵药品有限公司 | 四氢吡啶衍生物 |
| US20070142363A1 (en) | 2003-10-13 | 2007-06-21 | Actelion Pharmaceuticals Ltd | Novel diazabicyclonene derivatives and use thereof |
| US20070135405A1 (en) | 2003-10-23 | 2007-06-14 | Olivier Bezencon | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain |
| WO2005054243A1 (en) | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene derivatives and their use as renin inhibitors |
| US20070135406A1 (en) | 2003-12-05 | 2007-06-14 | Olivier Bezencon | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain |
| WO2006021401A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicylononene derivatives |
| JP2008510755A (ja) | 2004-08-25 | 2008-04-10 | アクテリオン ファーマシューティカルズ リミテッド | ビシクロノネン誘導体 |
| WO2006021399A2 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Azabicyclononene derivatives as renin inhibitors |
| WO2006021403A1 (en) | 2004-08-25 | 2006-03-02 | Actelion Pharmaceuticals Ltd | Bicyclononene derivatives |
| WO2006058546A1 (en) | 2004-12-01 | 2006-06-08 | Actelion Pharmaceuticals Ltd | Novel lactame derivatives as renin inhibitors |
| AR052263A1 (es) | 2004-12-08 | 2007-03-07 | Actelion Pharmaceuticals Ltd | Derivado de diazabiciclononeno |
| WO2006063610A1 (en) | 2004-12-17 | 2006-06-22 | Actelion Pharmaceuticals Ltd | Heteroaryl substituted diazabicyclononene derivatives |
| CA2595986A1 (en) | 2005-01-28 | 2006-08-03 | Actelion Pharmaceuticals Ltd | 7-{4-[2-(2,6-dichlor0-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amides as inhibitors of renin for the treatment of hypertension |
| WO2006092268A1 (en) | 2005-03-02 | 2006-09-08 | Actelion Pharmaceuticals Ltd | Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors |
| AR055756A1 (es) | 2005-03-31 | 2007-09-05 | Speedel Experimenta Ag | Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos |
| BRPI0609534A2 (pt) | 2005-03-31 | 2010-04-13 | Speedel Experimenta Ag | piperidinas 3,4,5-substituìdas |
| GB0510810D0 (en) * | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR100963455B1 (ko) | 2005-05-27 | 2010-06-18 | 액테리온 파마슈티칼 리미티드 | 신규한 피페리딘 카르복실산 아미드 유도체 |
| WO2006131884A2 (en) | 2005-06-07 | 2006-12-14 | Actelion Pharmaceuticals Ltd | Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors |
| WO2007009250A1 (en) | 2005-07-22 | 2007-01-25 | Merck Frosst Canada Ltd. | Renin inhibitors |
| WO2007034406A1 (en) | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
| WO2007034445A2 (en) | 2005-09-26 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency |
| WO2007049224A1 (en) | 2005-10-25 | 2007-05-03 | Actelion Pharmaceuticals Ltd | Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives |
| ES2430139T3 (es) | 2005-12-30 | 2013-11-19 | Novartis Ag | Compuestos de piperidina 3,5-sustituido como inhibidores de renina |
| EP1816122A3 (en) * | 2006-01-19 | 2007-09-19 | Speedel Experimenta AG | 3,4,5-substituted piperidines as therapeutic compounds |
| JP2009526767A (ja) | 2006-02-02 | 2009-07-23 | アクテリオン ファーマシューティカルズ リミテッド | 新規二級アミン |
| AU2007220149A1 (en) | 2006-03-03 | 2007-09-07 | Actelion Pharmaceuticals Ltd | Primary amines as renin inhibitors |
| TW200800897A (en) | 2006-03-08 | 2008-01-01 | Actelion Pharmaceuticals Ltd | New amines |
| ATE520690T1 (de) | 2006-09-18 | 2011-09-15 | Vitae Pharmaceuticals Inc | Piperidinderivate als renin-inhibitoren |
| WO2008058387A1 (en) * | 2006-11-17 | 2008-05-22 | Merck Frosst Canada Ltd. | Renin inhibitors |
| EP2162436A4 (en) * | 2007-05-24 | 2010-08-04 | Merck Frosst Canada Ltd | NEW CASE OF RENININHIBITORS |
| AU2008286178A1 (en) | 2007-08-07 | 2009-02-12 | Merck Frosst Canada Ltd | Renin inhibitors |
| WO2009070869A1 (en) | 2007-12-04 | 2009-06-11 | Merck Frosst Canada Ltd. | Renin inhibitors |
| US20110152316A1 (en) | 2008-05-22 | 2011-06-23 | Austin Chih-Yu Chen | 3,4-substituted piperidine derivatives as renin inhibitors |
| US20120190701A1 (en) | 2009-08-18 | 2012-07-26 | Merck Sharp & Dohme Corp. | Renin inhibitors |
-
2009
- 2009-05-04 CN CN200980116219.5A patent/CN102015682B/zh not_active Expired - Fee Related
- 2009-05-04 KR KR1020137003332A patent/KR20130029116A/ko not_active Withdrawn
- 2009-05-04 JP JP2011507765A patent/JP4790871B2/ja not_active Expired - Fee Related
- 2009-05-04 NZ NZ589019A patent/NZ589019A/xx not_active IP Right Cessation
- 2009-05-04 EP EP09741617.6A patent/EP2274295B1/en active Active
- 2009-05-04 BR BRPI0912388A patent/BRPI0912388A2/pt not_active Application Discontinuation
- 2009-05-04 CA CA2722734A patent/CA2722734C/en not_active Expired - Fee Related
- 2009-05-04 MX MX2010012067A patent/MX2010012067A/es active IP Right Grant
- 2009-05-04 ES ES09741617.6T patent/ES2548134T3/es active Active
- 2009-05-04 AU AU2009243875A patent/AU2009243875B2/en not_active Ceased
- 2009-05-04 EA EA201071269A patent/EA020853B1/ru not_active IP Right Cessation
- 2009-05-04 MY MYPI20105036 patent/MY152042A/en unknown
- 2009-05-04 WO PCT/CA2009/000611 patent/WO2009135299A1/en not_active Ceased
- 2009-05-04 KR KR1020107024856A patent/KR101403311B1/ko not_active Expired - Fee Related
- 2009-05-04 PL PL09741617T patent/PL2274295T3/pl unknown
- 2009-05-04 SG SG2013055702A patent/SG192543A1/en unknown
- 2009-05-04 US US12/990,927 patent/US8889714B2/en not_active Expired - Fee Related
-
2010
- 2010-10-04 IL IL208467A patent/IL208467A/en not_active IP Right Cessation
- 2010-11-03 DO DO2010000329A patent/DOP2010000329A/es unknown
- 2010-11-04 SV SV2010003723A patent/SV2010003723A/es not_active Application Discontinuation
- 2010-11-05 NI NI201000188A patent/NI201000188A/es unknown
- 2010-11-11 CO CO10141827A patent/CO6311081A2/es not_active Application Discontinuation
- 2010-11-11 MA MA33335A patent/MA32296B1/fr unknown
- 2010-11-24 CR CR11809A patent/CR11809A/es not_active Application Discontinuation
-
2011
- 2011-06-01 JP JP2011123057A patent/JP5653842B2/ja not_active Expired - Fee Related
- 2011-06-01 JP JP2011123054A patent/JP5587246B2/ja not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2570920A1 (en) * | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Piperidine derivatives as renin inhibitors |
| CA2587348A1 (en) * | 2004-12-30 | 2006-07-06 | Novartis Ag | Organic compounds |
| CA2590898A1 (en) * | 2005-01-14 | 2006-07-20 | Novartis Ag | 3,4,(5)-substituted tetrahvdropyridines |
| CA2598861A1 (en) * | 2005-03-09 | 2006-09-14 | Novartis Ag | Organic compounds |
| CA2609355A1 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Organic compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA020853B1 (ru) | 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина | |
| TWI762544B (zh) | 新穎cyp11a1抑制劑 | |
| JP2011520924A (ja) | レニン阻害剤としての3,4−置換ピペリジン誘導体 | |
| MX2013006974A (es) | Ureas asimetricas y usos medicos de las mismas. | |
| CA2555800C (en) | Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists | |
| JP2012511514A (ja) | レニン阻害剤としての3,4−置換ピペリジン誘導体 | |
| JPWO2009041559A1 (ja) | インダゾールアクリル酸アミド化合物 | |
| US20050176772A1 (en) | Pharmaceutically active compounds | |
| ES2394324T3 (es) | Piridinureas de nicotinamida como inhibidores de la cinasa del receptor del factor de crecimiento endotelial vascular (VEGF) | |
| TW201713622A (zh) | 含氮雜環化合物 | |
| EP3218363B1 (en) | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | |
| EP3212638B1 (en) | New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors | |
| TWI472524B (zh) | 腎素抑制劑 | |
| EA029430B1 (ru) | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина | |
| EP3212631B1 (en) | Pyrazolyl-3,4-dihydroquinolin-2-one aldosterone synthase inhibitors | |
| JP2005325031A (ja) | 1−シンナミルピペリジン誘導体 | |
| JPWO2001056988A1 (ja) | キナーゼ阻害活性を有する窒素含有化合物およびそれを含む医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |